Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. Two ...
The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and mainly be driven by an increase in approval of a ...
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
Gene Editing Tool Market AnalysisThe global gene editing tool market is on the cusp of a revolutionary expansion, projected to grow at an impressive CAGR of 18.4% from 2024 to 2034. Valued at USD 688.
Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.
Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...
“This dosing is a truly historic event – for science, for medicine, and most importantly for people living with this eye disease,” said Cynthia Collins, Editas’ chief executive. LCA is a ...
The global Gene Editing Market was valued at $5.1 billion in 2022 and is projected to reach $16.2 billion by 2030, growing at ...
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock. Separately ...